Anti-SORC3/ SORCS3/ SORCS monoclonal antibody

Anti-SORC3/ SORCS3/ SORCS antibody for FACS & in-vivo assay

Target products collectionGo to SORCS3/SORCS3 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP1694-Ab-1/ GM-Tg-hg-MP1694-Ab-2Anti-Human SORCS3 monoclonal antibodyHuman
GM-Tg-rg-MP1694-Ab-1/ GM-Tg-rg-MP1694-Ab-2Anti-Rat SORCS3 monoclonal antibodyRat
GM-Tg-mg-MP1694-Ab-1/ GM-Tg-mg-MP1694-Ab-2Anti-Mouse SORCS3 monoclonal antibodyMouse
GM-Tg-cynog-MP1694-Ab-1/ GM-Tg-cynog-MP1694-Ab-2Anti-Cynomolgus/ Rhesus macaque SORCS3 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP1694-Ab-1/ GM-Tg-felg-MP1694-Ab-2Anti-Feline SORCS3 monoclonal antibodyFeline
GM-Tg-cang-MP1694-Ab-1/ GM-Tg-cang-MP1694-Ab-2Anti-Canine SORCS3 monoclonal antibodyCanine
GM-Tg-bovg-MP1694-Ab-1/ GM-Tg-bovg-MP1694-Ab-2Anti-Bovine SORCS3 monoclonal antibodyBovine
GM-Tg-equg-MP1694-Ab-1/ GM-Tg-equg-MP1694-Ab-2Anti-Equine SORCS3 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP1694-Ab-1/ GM-Tg-hg-MP1694-Ab-2; GM-Tg-rg-MP1694-Ab-1/ GM-Tg-rg-MP1694-Ab-2;
GM-Tg-mg-MP1694-Ab-1/ GM-Tg-mg-MP1694-Ab-2; GM-Tg-cynog-MP1694-Ab-1/ GM-Tg-cynog-MP1694-Ab-2;
GM-Tg-felg-MP1694-Ab-1/ GM-Tg-felg-MP1694-Ab-2; GM-Tg-cang-MP1694-Ab-1/ GM-Tg-cang-MP1694-Ab-2;
GM-Tg-bovg-MP1694-Ab-1/ GM-Tg-bovg-MP1694-Ab-2; GM-Tg-equg-MP1694-Ab-1/ GM-Tg-equg-MP1694-Ab-2
Products NameAnti-SORCS3 monoclonal antibody
Formatmab
Target NameSORCS3
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-SORCS3 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species SORC3/ SORCS3/ SORCS VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP1694
    Target NameSORCS3
    Gene ID22986,66673,294043,693500,486879,101097597,531405,100069497
    Gene Symbol and Synonyms6330404A12Rik,SORCS,SORCS3
    Uniprot AccessionQ9UPU3
    Uniprot Entry NameSORC3_HUMAN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000156395
    Target ClassificationN/A

    The target: SORCS3, gene name: SORCS3, also named as SORCS. This gene encodes a type-I receptor transmembrane protein that is a member of the vacuolar protein sorting 10 receptor family. Proteins of this family are defined by a vacuolar protein sorting 10 domain at the N-terminus. The N-terminal segment of this domain has a consensus motif for proprotein convertase processing, and the C-terminal segment of this domain is characterized by ten conserved cysteine residues. The vacuolar protein sorting 10 domain is followed by a leucine-rich segment, a transmembrane domain, and a short C-terminal cytoplasmic domain that interacts with adaptor molecules. The transcript is expressed at high levels in the brain, and candidate gene studies suggest that genetic variation in this gene is associated with Alzheimer's disease. Consistent with this observation, knockdown of the gene in cell culture results in an increase in amyloid precursor protein processing. [provided by RefSeq, Dec 2014].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.